Galapagos begins trial with rheumatoid arthritis candidate drug (PharmaBiz)Information on Galapagos begins trial with rheumatoid arthritis candidate drug (PharmaBiz) under Arthritis section of the Health Articles & Reviews; Galapagos NV has initiated phase-I clinical development of its novel mechanism of action, first-in-class candidate drug GLPG0259 for rheumatoid arthritis (RA). GLPG0259 is the first ... |
![]() |
|
Galapagos begins trial with rheumatoid arthritis candidate drug (PharmaBiz)
by Dana_Gunderson 04-01-2009, 07:30 AM
Galapagos NV has initiated phase-I clinical development of its novel mechanism of action, first-in-class candidate drug GLPG0259 for rheumatoid arthritis (RA). GLPG0259 is the first small molecule from Galapagos' target discovery platform to enter the clinic.
More... |
|
Views 12
Comments 0
|
![]() |
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |